Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

June 21, 2018 Life Science Incubator Selects New QuickFire Challenge Winners to Join JLABS @ NYC NEW YORK, June 21, 2018 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced the opening of JLABS @ NYC. The 30,000-square foot facility, located at the New

Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018

Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018

BEERSE, Belgium, June 11, 2018 /PRNewswire/ — FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16

New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions

New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions

June 8, 2018 Featured Data Includes Findings From OBSERVE-4D – the Largest Real-World Study to Evaluate the Risk of Lower Extremity Amputation and Hospitalization for Heart Failure Several Comparative Studies Between INVOKANA® and Other Diabetes Medications, Including Glucagon-Like Peptide-1 Receptor

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

June 3, 2018 Treatment with investigational compound erdafitinib demonstrated durable responses in patients with metastatic urothelial cancer with genetic alterations Data featured for the first time as an oral presentation at ASCO 2018 (Abstract #4503) and selected for the Best

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma

June 1, 2018 Phase 3 data featured as oral presentation (abstract #8003), selected for Best of ASCO 2018 Meetings, and simultaneously published in The New England Journal of Medicine Study represents first randomized double-blind placebo-controlled trial evaluating treatment-naïve Waldenström’s macroglobulinemia

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen PISCATAWAY, N.J., May 30, 2018 /PRNewswire/ — Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration

Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

May 26, 2018 Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with previously treated non-small cell lung cancer to be terminated. Phase I MMY2036

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

May 21, 2018 Dolutegravir/rilpivirine, the result of a collaboration with ViiV Healthcare, offers a complete daily treatment regimen for virologically suppressed adults living with HIV-1 in a single-pill CORK, Ireland–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

PSA outcomes data from Phase 3 SPARTAN clinical trial and population-based study of PSA doubling time in patients with non-metastatic castration-resistant prostate cancer were presented at the AUA 2018 Annual Meeting HORSHAM, PA, May 18, 2018 – The Janssen Pharmaceutical Companies

Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

DARZALEX® is the first monoclonal antibody approved for newly diagnosed patients Today’s FDA approval of DARZALEX® in combination with bortezomib, melphalan and prednisone marks its fifth indication in multiple myeloma HORSHAM, PA, May 7, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression

Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups Study in elderly

J&J: Janssen to Present Data in Treatment-Resistant Depression, Schizophrenia, Health Economics and Outcomes and Population Health at American Psychiatric Association 2018 Meeting

Six esketamine nasal spray abstracts to be presented, including the first results from two Phase 3 studies and sub-analyses in U.S. patient populations Five INVEGA SUSTENNA®, INVEGA TRINZA® (paliperidone palmitate) abstracts to be presented, including a health economics and outcomes study

J&J: Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities HORSHAM, PA, May 2, 2018 – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a definitive agreement

J&J: Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy CHERRY HILL, NJ, AND ALLSCHWIL, SWITZERLAND – April 30,

J&J: Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes

First Real-World Study Comparing Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapies Also Showed Patients Taking INVOKANA® 300mg Were Significantly Less Likely to Discontinue Treatment or Switch to Another Diabetes Medicine TITUSVILLE, NJ, April 27, 2018 – The Janssen Pharmaceutical Companies of Johnson &